in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance....
.
.turn on desktop notifications for breaking stories about interest?.
crispr therapeutics, mgh team up on new cancer treatments.
'indian ip and liabilities law barrier to pharma r&d investment'
.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid..
.
.
.
former novartis exec to lead cambridge diabetes startup semma